OBJECTIVES

: To estimate the budget impact of incorporating Obinutuzumab in combination with bendamustine (G-Benda), cyclophosphamide-vincristine-prednisone (G-CVP) and cyclophosphamide-doxorubicin-vincristine-prednisone (G-CHOP), followed by obinutuzumab maintenance, compared to rituximab in combination with bendamustine (R-Benda), cyclophosphamide-vincristine-prednisone (R-CVP) and cyclophosphamide-doxorubicin-vincristine-prednisone (R-CHOP), ) for the treatment of advanced Non-Hodgkin Follicular Lymphoma (NHFL).

METHODS

: We compared the expected costs of NHFL patients, who received either biologic-chemotherapy followed by biologic maintenance from the Chilean public healthcare payer perspective, in accordance with ISPOR principle good practices. We estimated the budget impact at annual basis up to 5 years, assuming 100% reimbursement. Direct costs related to drug treatment, Supportive care and adverse events were considered in the analysis. A probabilistic sensitivity analysis was conducted to account for second order uncertainty of the model.

RESULTS

: The budget needed to implement obinutzumab for the first and second year was $ 979.026 and $ 1.286.535 USD respectively. The main driver of costs related to obinutuzumab coverage is given by the cost of the technology. From the probabilistic sensitivity analysis, the estimation of the budget impact ranges between $ 411.368 to $ 3.056.007 USD per year.

CONCLUSIONS : For the first year it was estimated a budget impact related to obinutuzumab coverage of $ 979.026 USD, which is explained almost entirely by the cost of innovative technology.